FSSAI Action Infant nutrition products are, among the closely regulated food categories. Infant nutrition products are designed for babies during stages of growth and development.,Any claim made on their packaging, promotional material or online listings can therefore attract serious regulatory attention. In a significant development, the Food Safety and Standards Authority of India, or FSSAI, has initiated action against Nestle India over issues linked to promotional claims made for some infant nutrition products and a separate concern involving the prescribed biotin level in a follow-up formula sample.
According to the reported details, FSSAI examined promotional material associated with NAN Excella Pro Stage 1 and Lactogen Pro 1, including information appearing on e-commerce platforms. The regulator raised concerns over claims such as “5 HMOs,” “Whey Protein,” and a statement describing whey protein as “easy to digest.”Authorities said these claims were not found to be in accordance with provisions governing foods meant for infant nutrition.
The case is important because infant formula advertising is governed by standards, than ordinary packaged food marketing. Regulators aim to prevent language that could influence parents or caregivers by suggesting additional superiority, health benefits or improved digestibility without meeting the applicable legal requirements.
A separate issue involves a follow-up formula manufactured by Nestle India. According to FSSAI, a tested sample did not meet the prescribed requirement for biotin. The sample was subsequently sent to a referral laboratory for re-analysis, where the reported non-conformity was also confirmed.
Following these findings, the regulator initiated three adjudication cases. However, it is important to understand the difference between a regulatory proceeding and a product ban. The initiation of adjudication does not automatically mean every batch of the affected products is unsafe or that the products have been banned across India.
For parents, the development highlights the importance of checking product labels, following official regulatory updates and consulting a paediatrician before making major changes to an infant’s feeding routine.
What Exactly Did FSSAI Flag in Nestle Products?
The regulatory action involves different types of compliance concerns. Two of them relate primarily to promotional claims, while another involves nutritional composition. FSSAI initiated separate adjudication proceedings after examining the products, promotional material and laboratory findings.
- NAN Excella Pro Stage 1: Claims related to “5 HMOs” and “Whey Protein” were questioned.
- Lactogen Pro 1: A claim describing whey protein as “easy to digest” was flagged.
- Follow-up Formula: A sample reportedly failed to meet the prescribed biotin requirement.
- Referral Testing: Re-analysis also reportedly found non-conformity.
- Regulatory Action: Three adjudication cases have been initiated.
Why Are Infant Food Promotional Claims So Strictly Regulated?
Infant food products are governed by specific regulatory requirements because infants represent a particularly sensitive consumer group.Regulators can examine whether the wording is permitted under the relevant infant nutrition rules and whether the claim may influence consumer decisions.
NAN Excella, Lactogen and Follow-up Formula: What Is the Difference?
The concerns reported in the three proceedings are not identical. The NAN Excella Pro Stage 1 and Lactogen Pro 1 matters focus on promotional claims, while the follow-up formula issue relates to nutritional composition and laboratory testing.
| Product/Category | Issue Flagged by FSSAI | Type of Concern | Reported Status |
|---|
| NAN Excella Pro Stage 1 | “5 HMOs” and “Whey Protein” claims | Promotional claim compliance | Adjudication case initiated |
| Lactogen Pro 1 | “Whey Protein easy to digest” claim | Promotional claim compliance | Adjudication case initiated |
| Follow-up Formula | Biotin below prescribed requirement | Nutritional composition | Case initiated after laboratory findings |
What Does the FSSAI-Nestle Case Mean?
The FSSAI action involving Nestle India highlights how closely infant nutrition products are monitored in India. Regulatory authorities have raised concerns about promotional claims associated with NAN Excella Pro Stage 1 and Lactogen Pro 1, while a separate follow-up formula sample was reportedly found not to comply with the prescribed biotin requirement.
Three adjudication cases have consequently been initiated. The proceedings will determine the regulatory outcome, responsibility and any corrective action that may be required.For customers the biggest thing is to tell the difference between being watched by regulators and having the product completely taken off the shelves. Parents should not think that every single batch or every Nestle baby food product is not safe just because some actions have started.
They should look at the FSSAI messages check the boxes and the batch numbers very carefully follow the instructions, for making the food and talk to a doctor before making big changes to a babys food.
READ MORE,
FAQs
1. Why has FSSAI taken action against Nestle India?
FSSAI has initiated regulatory proceedings over certain promotional claims involving infant nutrition products and a separate biotin-related non-compliance reported in a follow-up formula sample.
2. Which Nestle products were mentioned in the promotional claims issue?
The reported products include NAN Excella Pro Stage 1 and Lactogen Pro 1.
3. What was the biotin-related issue?
A follow-up formula sample manufactured by Nestle India was reportedly found not to meet the prescribed biotin requirement during laboratory testing and subsequent re-analysis.
4. Have NAN Excella Pro Stage 1 and Lactogen Pro 1 been banned in India?
The reported action concerns adjudication proceedings. It should not automatically be interpreted as a nationwide blanket ban unless an official regulatory authority separately announces one.
5. Should parents immediately stop using infant formula?
Parents should not suddenly stop or replace an infant formula based only on a news report. They should check official advisories and consult a paediatrician before making feeding changes.
